REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS

6 Months Ended

Jun. 30, 2026

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS

NOTE 22 - REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS

As discussed in Note 2, in preparing the unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2026, we identified an error in our previously issued interim financial statements as of and for the three months ended March 31, 2026 related to the timing of revenue recognition between interim periods. The error resulted in an overstatement of revenues for the three months ended March 31, 2026.

We evaluated the error, individually and in the aggregate, and concluded that it was not material to the previously issued financial statements as of and for the three months ended March 31, 2026. Accordingly, we have revised the previously reported March 31, 2026 financial information to correct the error.

The following tables present the impact of the revision on the affected line items in our previously reported (a) condensed consolidated balance sheet as of March 31, 2026; (b) condensed consolidated statement of operations for the three months ended March 31, 2026; (c) condensed consolidated statement of deficit for the three months ended March 31, 2026; and (d) condensed consolidated statement of cash flows for the three months ended March 31, 2026.

CONDENSED CONSOLIDATED BALANCE SHEET

March 31, 2026

(Unaudited)

	As Reported			Revision			As Revised
ASSETS
Current assets:
Cash	$	211,911		$	-		$	211,911
Accounts receivable, net		330,348			(151,200	)		179,148
Grant receivable		121,720			-			121,720
Inventory		143,425			-			143,425
Prepaid expenses		212,810			-			212,810
Total current assets		1,020,214			(151,200	)		869,014

Property and equipment, net		1,452			-			1,452

Right to use assets		148,604			-			148,604

Other assets:
Intangible assets, net		549,501			-			549,501
Goodwill		563,158			-			563,158
Deposits, long term		41,936			-			41,936
Total other assets		1,154,595			-			1,154,595

Total assets	$	2,324,865			(151,200	)	$	2,173,665

LIABILITIES AND DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	6,585,014			-		$	6,585,014
Lease liability, short term		44,255			-			44,255
Notes payable, net of debt discount		1,239,434			-			1,239,434
Notes payable, related parties, net of debt discount		658,263			-			658,263
Total current liabilities		8,526,966			-			8,526,966

Long term liabilities:
Economic Injury Disaster loan, long term		69,155			-			69,155
Royalty liability		351,492			-			351,492
Royalty obligation, net of discount		4,896,172			-			4,896,172
Lease liability, long term		104,349			-			104,349

Total liabilities		13,948,134			-			13,948,134

Commitments and contingencies

Deficit:
Preferred stock, no par value, 600,000 authorized
Series A convertible preferred stock, no par value; 80,000 designated; 80,000 shares issued and outstanding as of March 31, 2026		16,000			-			16,000
Series B convertible preferred stock, no par value; 160,000 designated; 160,000 shares issued and outstanding as of March 31, 2026		5,616			-			5,616
Common stock, $0.001 par value; 750,000,000 shares authorized, 28,906,559 shares issued and outstanding as of March 31, 2026		28,906			-			28,906
Common stock subscribed		100,000			-			100,000
Additional paid in capital		75,879,983			-			75,879,983
Accumulated deficit		(87,480,515	)		(114,609	)		(87,595,124	)
Total deficit attributable to BioCorRx Inc.		(11,450,010	)		(114,609	)		(11,564,619	)
Non-controlling interest		(173,259	)		(36,591	)		(209,850	)
Total deficit		(11,623,269	)		(151,200	)		(11,774,469	)

Total liabilities and deficit	$	2,324,865			(151,200	)	$	2,173,665

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

Three Months ended March 31, 2026

(Unaudited)

	As Reported			Revision			As Revised
Revenues, net	$	214,539		$	(135,471	)	$	79,068

Operating expenses:
Cost of goods sold		25,184			-			25,184
Research and development		352,333			-			352,333
Selling, general and administrative		775,453			15,729			791,182
Impairment of intellectual property		6,374			-			6,374
Depreciation and amortization		11,195			-			11,195
Total operating expenses		1,170,539			15,729			1,186,268

Loss from operations		(956,000	)		(151,200	)		(1,107,200	)

Other income (expenses):
Interest expense - related parties		(135,448	)		-			(135,448	)
Interest expense, net		(31,041	)		-			(31,041	)
Loss on settlement of debt		(100,000	)		-			(100,000	)
Grant income		362,597			-			362,597
Total other income		96,108			-			96,108

Loss before provision for income taxes		(859,892	)		(151,200	)		(1,011,092	)

Income taxes		-			-			-

Net loss		(859,892	)		(151,200	)		(1,011,092	)

Non-controlling interest		28,665			36,591			65,256

Net loss attributable to BioCorRx Inc.	$	(831,227	)	$	(114,609	)	$	(945,836	)

Net loss per common share, basic and diluted	$	(0.03	)	$	(0.01	)	$	(0.04	)

Weighted average number of common shares outstanding, basic and diluted		25,599,642			-			25,599,642

CONDENSED CONSOLIDATED STATEMENT OF DEFICIT

Three Months ended March 31, 2026

As Reported

	Series A				Series B
	Convertible				Convertible								Common		Additional						Non-
	Preferred stock				Preferred stock				Common stock				stock		Paid in			Accumulated			Controlling
	Shares		Amount		Shares		Amount		Shares		Amount		Subscribed		Capital			Deficit			Interest			Total
Balance, December 31, 2025		80,000	$	16,000		160,000	$	5,616		24,489,311	$	24,489	$	100,000	$	75,279,624		$	(86,649,288	)	$	(303,429	)	$	(11,526,988	)
Common stock issued for services rendered		-		-		-		-		289,171		289		-		108,086			-			-			108,375
Common stock issued in connection with subscription agreement		-		-		-		-		1,470,588		1,471		-		498,529			-			-			500,000
Common stock issued in connection with conversion of promissory notes		-		-		-		-		294,118		294		-		99,706			-			-			100,000
Common stock issued in connection with acquisition of non-controlling interest		-		-		-		-		2,263,371		2,263		-		(161,098	)		-			158,835			-
Common stock issued in connection with issuance of promissory notes		-		-		-		-		100,000		100		-		39,900			-			-			40,000
Imputed interest for related party advances		-		-		-		-		-		-		-		15,236			-			-			15,236
Net loss		-		-		-		-		-		-		-		-			(831,227	)		(28,665	)		(859,892	)
Balance, March 31, 2026 (unaudited)		80,000	$	16,000		160,000	$	5,616		28,906,559	$	28,906	$	100,000	$	75,879,983		$	87,480,515	)	$	(173,259	)	$	(11,623,269	)

Revison

	Series A				Series B
	Convertible				Convertible								Common		Additional					Non-
	Preferred stock				Preferred stock				Common stock				stock		Paid in		Accumulated			Controlling
	Shares		Amount		Shares		Amount		Shares		Amount		Subscribed		Capital		Deficit			Interest			Total
Balance, December 31, 2025		-	$	-		-	$	-		-	$	-	$	-	$	-	$	-		$	-		$	-
Common stock issued for services rendered		-		-		-		-		-		-		-		-		-			-			-
Common stock issued in connection with subscription agreement		-		-		-		-		-		-		-		-		-			-			-
Common stock issued in connection with conversion of promissory notes		-		-		-		-		-		-		-		-		-			-			-
Common stock issued in connection with acquisition of non-controlling interest		-		-		-		-		-		-		-		-		-			-			-
Common stock issued in connection with issuance of promissory notes		-		-		-		-		-		-		-		-		-			-			-
Imputed interest for related party advances		-		-		-		-		-		-		-		-		-			-			-
Net loss		-		-		-		-		-		-		-		-		(114,609	)		(36,591	)		151,200	)
Balance, March 31, 2026 (unaudited)		-	$	-		-	$	-		-	$	-	$	-	$	-	$	(114,609	)	$	(36,591	)	$	(151,200	)

As Revised

	Series A				Series B
	Convertible				Convertible								Common		Additional						Non-
	Preferred stock				Preferred stock				Common stock				stock		Paid in			Accumulated			Controlling
	Shares		Amount		Shares		Amount		Shares		Amount		Subscribed		Capital			Deficit			Interest			Total
Balance, December 31, 2025		80,000	$	16,000		160,000	$	5,616		24,489,311	$	24,489	$	100,000	$	75,279,624		$	(86,649,288	)	$	(303,429	)	$	(11,526,988	)
Common stock issued for services rendered		-		-		-		-		289,171		289		-		108,086			-			-			108,375
Common stock issued in connection with subscription agreement		-		-		-		-		1,470,588		1,471		-		498,529			-			-			500,000
Common stock issued in connection with conversion of promissory notes		-		-		-		-		294,118		294		-		99,706			-			-			100,000
Common stock issued in connection with acquisition of non-controlling interest		-		-		-		-		2,263,371		2,263		-		(161,098	)		-			158,835			-
Common stock issued in connection with issuance of promissory notes		-		-		-		-		100,000		100		-		39,900			-			-			40,000
Imputed interest for related party advances		-		-		-		-		-		-		-		15,236			-			-			15,236
Net loss		-		-		-		-		-		-		-		-			(945,836	)		(65,256	)		(1,011,092	)
Balance, March 31, 2026 (unaudited)		80,000	$	16,000		160,000	$	5,616		28,906,559	$	28,906	$	100,000	$	75,879,983		$	(87,595,124	)	$	(209,850	)	$	(11,774,469	)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

Three Months ended March 31, 2026

(Unaudited)

	As Reported			Revision			As Revised
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(859,892	)	$	(151,200	)	$	(1,011,092	)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization		11,195			-			11,195
Amortization of discount on royalty obligation		115,334			-			115,334
Impairment of intellectual property		6,374			-			6,374
Amortization of right-of-use asset		10,524			-			10,524
Loss on settlement of debt		100,000			-			100,000
Stock based compensation		108,375			-			108,375
Imputed interest for related party advances		15,236			-			15,236
Changes in operating assets and liabilities:
Accounts receivable		(76,889	)		151,200			74,311
Grant receivable		(69,694	)		-			(69,694	)
Prepaid expenses		13,388			-			13,388
Accounts payable and accrued expenses		253,990			-			253,990
Royalty liability		(7,886	)					(7,886	)
Upfront purchase price liability		(42,503	)		-			(42,503	)
Lease liability		(10,523	)		-			(10,523	)
Net cash used in operating activities		(432,971	)		-			(432,971	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock subscription and royalty agreement		500,000			-			500,000
Payment to Economic Injury Disaster loan		(382	)		-			(382	)
Payment of notes payable – related party		5,000	)		-			(5,000	)
Payment of notes payable		(75,000	)		-			(75,000	)
Proceeds from notes payable – related party		85,904			-			85,904
Net cash provided by financing activities		505,522			-			505,522

Net increase in cash		72,551			-			72,551
Cash, beginning of period		139,360			-			139,360

Cash, end of period	$	211,911		$	-		$	211,911

Supplemental disclosures of cash flow information:
Interest paid	$	707		$	-		$	707
Taxes paid	$	-		$	-		$	-
Common stock issued in connection with conversion of related party promissory note	$	100,000		$	-		$	100,000
Common stock issued in connection with issuance of promissory notes	$	40,000		$	-		$	40,000